Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

GlobalData, January 2012, Pages: 74

Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018

Summary

GlobalData, the industry analysis specialist, has released its new report, “Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Growth Hormone Deficiency (GHD) Therapeutics market. The report identifies the key trends shaping and driving the global Growth Hormone Deficiency (GHD) Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Growth Hormone Deficiency (GHD) Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Growth Hormone Deficiency (GHD) Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Growth Hormone Deficiency (GHD) Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2018.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Growth Hormone Deficiency (GHD) Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Growth Hormone Deficiency (GHD) Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Growth Hormone Deficiency (GHD) Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Growth Hormone Deficiency (GHD) Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Growth Hormone Deficiency (GHD) Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Growth Hormone Deficiency (GHD) Therapeutics market landscape? – Identify, understand and capitalize.

Keywords

Pharma, Pharmaceuticals, Healthcare, Deal Value, Deal Volume, Private Equity, Venture Capital, Partnership, Licensing, Agreements, North America, Europe, Asia-Pacific, Rest of the World (ROW), Merger, M&A, Acquisition, Equity Offering, Debt Offering, Capital raising, Asset Purchase, Private Placement, Secondary offering, IPO, Initial Public Offer, cardiovascular, central nervous system, dermatology, ear nose throat disorders, gastrointestinal, genito urinary system and sex hormones, hematological disorders, hormonal disorders, immunology, infectious disease, male health, metabolic disorders, mouth and dental disorders, musculoskeletal, oncology, ophthalmology, respiratory, toxicology, women's health, Upfront Payment, Milestone Payment, Phases, Clinical Trials

1
1

1.1 List of Tables
1.2 List of Figures
2 Growth Hormone Deficiency (GHD) Therapeutics - Introduction
2.1 Disease Overview
2.2 Epidemiology
2.3 Etiology
2.4 Pathophysiology
2.5 Signs and Symptoms
2.5.1 Children
2.5.2 Adults
2.6 Commonly Used Diagnostic Tests
2.6.1 Growth Hormone Response is Measured against Insulin Induced Hypoglycemia
2.6.2 Growth Hormone Response to Arginine/Growth Hormone Releasing Hormone (GHRH) Infusion
2.6.3 Radiological Investigations
2.7 Treatment and Management Options for Growth Hormone Deficiency
2.7.1 Factors affecting GH dosing
2.7.2 GH replacement therapy in adults with GHD
2.7.3 GH replacement therapy in children with GHD
2.8 GlobalData Pipeline Report Guidance
3 GHD Therapeutics - Market Characterization
3.1 GHD Therapeutics Market Size (2005-2010) - Global
3.2 GHD Therapeutics Market Forecast (2010-2018) - Global
3.3 GHD Therapeutics Market Size (2005-2010) - The US
3.4 GHD Therapeutics Market Forecast (2010-2018) - The US
3.5 GHD Therapeutics Market Size (2005-2010) - France
3.6 GHD Therapeutics Market Forecast (2010-2018) - France
3.7 GHD Therapeutics Market Size (2005-2010) - Germany
3.8 GHD Therapeutics Market Forecast (2010-2018) - Germany
3.9 GHD Therapeutics Market Size (2005-2010) - Italy
3.10 GHD Therapeutics Market Forecast (2010-2018) - Italy
3.11 GHD Therapeutics Market Size (2005-2010) - Spain
3.12 GHD Therapeutics Market Forecast (2010-2018) - Spain
3.13 GHD Therapeutics Market Size (2005-2010) - The UK
3.14 GHD Therapeutics Market Forecast (2010-2018) - The UK
3.15 GHD Therapeutics Market Size (2005-2010) - Japan
3.16 GHD Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the GHD Therapeutics Market
3.17.1 Drivers for the GHD Therapeutics Market
3.17.2 Barriers for the GHD Therapeutics Market
3.18 Opportunity and Unmet Need Analysis
3.19 Key Takeaway
4 GHD Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profiles for the Major Marketed Products in the GHD Therapeutics Market
4.3.1 Nutropin AQ
4.3.2 Humatrope
4.3.3 Genotropin
4.3.4 Saizen
4.3.5 Norditropin
4.3.6 Omnitrope
4.3.7 Increlex
4.4 Key Takeaway
5 GHD Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 GHD Therapeutics Pipeline - Pipeline by Phases of Development
5.3.1 GHD Therapeutics -Regulatory Filed and Phase III Clinical Pipeline
5.3.2 GHD Therapeutics - Phase II Pipeline
5.3.3 GHD Therapeutics - Phase I Pipeline
5.3.4 GHD Therapeutics - Preclinical
5.3.5 GHD Therapeutics - Discovery
5.3.6 GHD Therapeutics - Unknow Phase
5.3.7 Technology Trends Analytic Framework
5.4 GHD Therapeutics Market - Pipeline by Mechanism of Action
5.5 GHD Therapeutics - Promising Drugs in Clinical Development
5.6 Molecule Profile for Promising Drugs in Clinical Development
5.6.1 LB03002 (SR-recombinant hGH)
5.7 Key Takeaway
6 GHD Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region and Country
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Clinical Trials Mapping by Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in GHD Therapeutics Clinical Trials
7 GHD Therapeutics - Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 GHD Therapeutics: Implications for Future Market Competition
8 GHD Therapeutics Market - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 BioPartners GmbH
8.2.2 LG Life Sciences, Ltd.
8.2.3 Ipsen S.A.
8.2.4 EMD Serono, Inc.
8.2.5 Theratechnologies Inc.
8.2.6 Eli Lilly and Company
8.2.7 Ambrx, Inc.
9 GHD Therapeutics - Licensing and Partnership Deals
10 GHD Therapeutics - Appendix
10.1 Market Definitions
10.2 Acronyms
10.3 Research Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Major Marketed Products in The US and EU5
Table 2: GH Replacement Therapy in Adults with GHD
Table 3: GHD Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 4: GHD Therapeutics Market, Global, Forecast ($m), 2010-2018
Table 5: GHD Therapeutics Market, The US, Revenue ($m), 2005-2010
Table 6: GHD Therapeutics Market, The US, Forecasts ($m), 2010-2018
Table 7: GHD Therapeutics Market, France, Revenue ($m), 2005-2010
Table 8: GHD Therapeutics Market, France, Forecasts ($m), 2010-2018
Table 9: GHD Therapeutics Market, Germany, Revenue ($m), 2005-2010
Table 10: GHD Therapeutics Market, Germany, Forecasts ($m), 2010-2018
Table 11: GHD Therapeutics Market, Italy, Revenue ($m), 2005-2010
Table 12: GHD Therapeutics Market, Italy, Forecasts ($m), 2010-2018
Table 13: GHD Therapeutics Market, Spain, Revenue ($m), 2005-2010
Table 14: GHD Therapeutics Market, Spain, Forecasts ($m), 2010-2018
Table 15: GHD Therapeutics Market, The UK, Revenue ($m), 2005-2010
Table 16: GHD Therapeutics Market, The UK, Forecasts ($m), 2010-2018
Table 17: GHD Therapeutics Market, Japan, Revenue ($m), 2005-2010
Table 18: GHD Therapeutics Market, Japan, Forecasts ($m), 2010-2018
Table 19: Pharmaceutical Company’s Patient Assistance Programs
Table 20: Major Marketed Products in GHD Therapeutics Market
Table 21: GHD Therapeutics- Regulatory Filed and Phase III Pipeline, 2011
Table 22: GHD Therapeutics - Phase II Pipeline, 2011
Table 23: GHD Therapeutics - Phase I Pipeline, 2011
Table 24: GHD Therapeutics - Preclinical Phase Pipeline, 2011
Table 25: GHD Therapeutics - Discovery Phase Pipeline, 2011
Table 26: GHD Therapeutics - Unknown Phase, 2011
Table 27: GHD Therapeutics - Most Promising Drug In Clinical Development, 2011
Table 28: GHD Therapeutics - Clinical Trials by Country, 2011
Table 29: GHD Therapeutics - Clinical Trials by Phase, 2011
Table 30: GHD Therapeutics - Clinical Trials by Status, 2011
Table 31: GHD Therapeutics - Overall Sponsors, 2011
Table 32: GHD Therapeutics - Prominent Sponsors, 2011
Table 33: GHD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 34: BioPartners GmbH, Pipeline - 2011
Table 35: LG Life Sciences, Pipeline- 2011
Table 36: Ipsen S.A., Pipeline- 2011
Table 37: EMD Serono, Inc., Pipeline- 2011
Table 38: Theratechnologies Inc., Pipeline- 2011
Table 39: Ambrx, Inc., Pipeline- 2011
Table 40: GHD-Global, Deals, 2011

1.2 List of Figures
Figure 1: Etiology of Growth Hormone Deficiency
Figure 2: Re-evaluation of GH and IGF-1 Levels- End of Growth in GHD Children
Figure 3: GHD Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 4: GHD Therapeutics Market, Global, Forecast ($m), 2010-2018
Figure 5: GHD Therapeutics Market, The US, Forecast ($m), 2005-2010
Figure 6: GHD Therapeutics Market, The US, Forecasts ($m), 2010-2018
Figure 7: GHD Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 8: GHD Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 9: GHD Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 10: GHD Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 11: GHD Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 12: GHD Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 13: GHD Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 14: GHD Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 15: GHD Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 16: GHD Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 17: GHD Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 18: GHD Therapeutics Market, Japan, Forecasts ($m), 2010-2018
Figure 19: Barriers To The Development of Biogenerics
Figure 20: Opportunity and Unmet Need in the GHD Therapeutics Market
Figure 21: GHD Therapeutics - Strategic Competitor Assessment, 2011
Figure 22: GHD Therapeutics - Pipeline by Phase of Development, 2011
Figure 23: GHD Therapeutics - Technology Trends Analytics Framework, 2011
Figure 24: GHD Therapeutics - Technology Trends Analytics Framework - Description, 2011
Figure 25: GHD Therapeutics - Pipeline by Mechanism of Action, 2011
Figure 26: GHD Therapeutics - Clinical Trials by Country, 2011
Figure 27: GHD Therapeutics - Clinical Trials by Phase, 2011
Figure 28: GHD Therapeutics - Clinical Trials by Status, 2011
Figure 29: GHD Therapeutics- Overall Sponsors, 2011
Figure 30: GHD Therapeutics - Prominent Sponsors, 2011
Figure 31: GHD Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 32: GHD Therapeutics Market, Drivers and Barriers, 2011
Figure 33: Implications for Future Market Competition in the GHD Therapeutics Market, 2011
Figure 34: GHD Therapeutics Market- Clinical Pipeline by Company, 2011
Figure 35: GlobalData Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Growth Hormone Deficiency (GHD) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information on the global GHD therapeutics market, and provides analysis of a number of key areas. The report identifies the key trends shaping and driving the global GHD therapeutics market and provides insights into the current competitive landscape and emerging companies expected to significantly alter the market positioning of current market leaders. Most importantly, the report provides valuable insights into the pipeline products within the global GHD sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
GHD Therapeutics Market Forecast to Display Steady Growth until 2018

GlobalData estimates that the global GHD therapeutics market was valued at $1,354.5m in 2010, after increasing at a Compound Annual Growth Rate (CAGR) of 4.0% during 2005–2010. The market is expected to record a CAGR of 3.7% from 2010–2018, to value $1,804.7m by 2018. The growth recorded in GHD therapeutics market during 2005-2010 can be attributed to the increase in the annual cost of therapy of existing treatment options. Aside from these, there are limited numbers of biosimilar formulations such as Omnitrope (somatropin), Valtropin (somatropin) in the GHD therapeutics market. The launches of biosimilars have a modest impact on the market because of the existing availability of these products at a competitive price. Omnitrope was the first biosimilar approved in GHD therapeutics market by the US Food and Drug Administration (US FDA) after long delays and court proceedings in May 2006. Omnitrope was approved by EMEA (European Medicines Agency) in April 2006. The GHD therapeutics market is expected to grow steadily during the forecast period; the expected launch of the sustained release formulation of LB03002 recombinant human growth hormone (hGH), which has a once weekly dosage schedule, will act as a major breakthrough in Growth Hormone (GH) therapy. The anticipated launch of this improved formulation of the existing product will increase patient compliance, and therefore will result in improved efficacy.

BioPartners GmbH
LG Life Sciences, Ltd.
Ipsen S.A.
EMD Serono, Inc.
Theratechnologies Inc.
Eli Lilly and Company
Ambrx, Inc.

Customers who bought this item also bought

• Medical Nutrition - A Global Market Overview
• Diabetes Diagnostics - Global Strategic Business Report
• Disinfectants - Global Strategic Business Report
• Overactive Bladder (OAB) Therapeutics - Global Strategic Business Report
• Private Healthcare - Global Strategic Business Report
• Molecular Diagnostics - Global Strategic Business Report
• Global Osteoporosis Therapeutics Market: Market Forecast, Patient Flow,Competitive Landscape, and Pipeline Analysis
• Cord Blood Stem Cells – A Global Market Overview
• Syringes (Disposable and Reusable) - Global Strategic Business Report
• Medical Oxygen Systems - Global Strategic Business Report